Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 
Press Release
 View printer-friendly version << Back

Target Cancer Metabolism Conference to Feature Three Presentations by Agios Scientists

Cambridge, Mass. – January 28, 2013 – Agios Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, today announced that Agios scientists will give three presentations at the Target Cancer Metabolism conference being held January 29-31, 2013 in Boston.

“Research and interest in cancer metabolism continues to accelerate, as this conference demonstrates,” said Scott Biller, Ph.D., chief scientific officer. “Taken together, our talks illustrate the innovative research capabilities and the insights into novel targets in metabolism that make Agios a leader in the field. In particular, we look forward to sharing data from our lead IDH1 and IDH2 programs, which we believe have significant potential to help patients with tumors carrying IDH mutations.”

The schedule for Agios’ presentations is as follows:

Date & Time: Wednesday, January 30, 2013 at 1:45 p.m. (EST)
Title: Using High Throughput Metabolomics, Flux Analysis, and Target Discovery to Target Novel Pathways in Cancer
Presenter: Edward Driggers, senior director, cell metabolism 

Date & Time: Wednesday, January 30, 2013 at 4:45 p.m. (EST)
Title: Case Study: IDH Mutations and Tumorigenecity
Presenter: Katharine Yen, director, biology

Date & Time: Thursday, January 31, 2013 at 1:30 p.m. (EST)
Title: Case Study: Structure-Function Studies of a Glutaminase Inhibitor Complex 
Presenter: Byron DeLaBarre, associate director, biochemistry 

About Agios Pharmaceuticals, Inc.

Agios is the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases. Agios has multiple first-in-class programs in cancer metabolism and inborn errors of metabolism advancing toward the clinic, in addition to an active research and discovery pipeline across both therapeutic areas. The company has a significant collaboration with Celgene focused on developing new treatments for cancer leveraging Agios’ capabilities and insights into cancer metabolism. For more information, please visit our website at www.agios.com.